Next 10 |
home / stock / argx / argx articles
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patien...
Needham initiated coverage on Cartesian Therapeutics Inc (NASDAQ:RNAC), a private company that went public in November following its...
RHO study supports proof-of-concept in primary Sjogren's disease Decision informed by favorable safety profile and consisten...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
VYVGART® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP) Regulatory decision in Japan...
Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected se...
U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Thursday. Shares of Guess?, Inc. (NYSE: GES) rose sharply during Th...
Thursday, Argenx SE (NASDAQ:ARGX) shares are trading higher in reaction to Chugai Pharmaceutical Co Ltd’s disappointing g...
Shares of Micron Technology, Inc. (NASDAQ: MU) rose sharply in today’s pre-market trading as the company reported upbeat results for its sec...
News, Short Squeeze, Breakout and More Instantly...
argenx SE Company Name:
ARGX Stock Symbol:
NASDAQ Market:
2024-04-18 12:15:04 ET Wells Fargo analyst issues SECTOR PERFORM recommendation for ARGX on April 18, 2024 10:01AM ET. The previous analyst recommendation was Sector Perform. ARGX was trading at $363.76 at issue of the analyst recommendation. The overall analyst consensu...
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patien...
ADHERE data show VYVGART ® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART ® treatment April 16, 2024...